Loading people...
Frances H. Arnold is a distinguished Nobel laureate in Chemistry and a Venture Partner at Catalio Capital. She is also a Professor of Chemical Engineering, Bioengineering, and Biochemistry at Caltech, renowned for her pioneering work in directed evolution.
As a Venture Partner at Catalio Capital, Frances H. Arnold focuses on investing in breakthrough biomedical technologies, life science innovations, biotechnology, synthetic biology, and enzyme engineering. Her expertise guides investments in areas poised to revolutionize healthcare and sustainable industries.
Frances H. Arnold works as a Venture Partner at Catalio Capital, a venture capital firm focused on breakthrough biomedical technologies. She also holds a professorship at the California Institute of Technology (Caltech).
Frances Arnold is a Venture Partner at Catalio Capital Management and the Linus Pauling Professor of Chemical Engineering, Bioengineering, and Biochemistry at Caltech in Pasadena, California. She was the first American woman to win the Nobel Prize in Chemistry in 2018 for pioneering the directed evolution of enzymes to create enhanced proteins. Holding over sixty patents, she has co-founded biotechnology companies including Gevo and Provivi after earning her undergraduate and graduate degrees from Princeton University and UC Berkeley. In addition to her academic roles, Arnold serves on the board of directors for Alphabet and Illumina and was appointed Co-Chair of President Biden's Council of Advisors on Science and Technology in 2021. Her current laboratory work focuses on advancing synthetic biology, sustainable green chemistry, and breakthrough biomedical technologies by combining machine learning with advanced protein engineering and biocatalysis.
Frances H. Arnold stands as a towering figure in both the scientific community and the venture capital landscape, serving as a distinguished Venture Partner at Catalio Capital. A recipient of the 2018 Nobel Prize in Chemistry for her pioneering work in directed evolution, Dr. Arnold brings an unparalleled depth of scientific insight and strategic vision to the firm’s investment activities. Her role at Catalio Capital is pivotal, focusing on identifying, evaluating, and nurturing breakthrough biomedical technologies and life science innovations that have the potential to reshape global health and industry.
At Catalio Capital, Dr. Arnold leverages her profound expertise to guide investment decisions, providing critical scientific diligence and strategic mentorship to portfolio companies. As a Venture Partner, she plays a crucial role in assessing the scientific merit and market potential of nascent technologies, ensuring that Catalio invests in ventures with robust scientific foundations and transformative capabilities. Her involvement helps bridge the gap between cutting-edge academic research and successful commercial application, a hallmark of Catalio’s investment philosophy.
Dr. Arnold’s investment focus areas are deeply rooted in her groundbreaking scientific career. She is particularly interested in biotechnology, synthetic biology, enzyme engineering, and other deep tech applications that promise advancements in therapeutics, diagnostics, sustainable chemistry, and advanced materials. Her work in directed evolution, which enables the engineering of enzymes with novel functions, has profound implications for developing more efficient and environmentally friendly industrial processes, as well as new pharmaceutical compounds. This expertise directly informs her ability to spot the next generation of disruptive innovations in these fields.
Before joining Catalio Capital, Frances H. Arnold established an illustrious career as a Professor of Chemical Engineering, Bioengineering, and Biochemistry at the California Institute of Technology (Caltech). Her research at Caltech revolutionized the field of protein engineering, demonstrating how evolutionary principles can be harnessed in the laboratory to create enzymes and biological systems with tailored properties. This work not only earned her the Nobel Prize but also laid foundational groundwork for numerous applications across medicine, energy, and manufacturing. Her academic leadership and relentless pursuit of scientific discovery have made her a globally recognized authority.
While specific individual investments by Dr. Arnold as a Venture Partner are often part of Catalio Capital’s broader portfolio strategy, her influence is evident in the firm’s commitment to backing scientifically rigorous and potentially paradigm-shifting companies. Her guidance helps Catalio identify and support ventures that are at the forefront of biomedical innovation, from novel drug discovery platforms to advanced gene editing technologies. Her unique perspective, combining a Nobel laureate’s scientific rigor with an investor’s strategic acumen, makes her an invaluable asset in Catalio Capital’s mission to invest in and accelerate the development of the most promising biomedical breakthroughs. Her presence underscores Catalio’s dedication to intellectual leadership and scientific excellence in the venture capital space.
